Literature DB >> 22351433

Cognitive impairment associated with schizophrenia: a review of the humanistic burden.

Helen Kitchen1, Diana Rofail, Louise Heron, Pat Sacco.   

Abstract

INTRODUCTION: Nearly every individual with schizophrenia is affected by cognitive decline. The aim of this literature review was to: (a) describe the humanistic burden of cognitive impairment associated with schizophrenia (CIAS); (b) develop a conceptual model that depicts the signs and symptoms of CIAS along with key concepts important to patients; and (c) consider the adequacy of potential patient-reported outcome (PRO) instruments for assessing future treatments.
METHODS: The following electronic databases were searched for articles published between January 1999 and November 2009 related to CIAS and PROs, or cost of illness: Medline; Embase; PsycINFO; the Health Economic Evaluation Database; and the National Health Service Economic Evaluation Database and Health Technology Assessment databases at the Centre for Reviews and Dissemination, University of York.
RESULTS: The literature search revealed 3950 abstracts, of which 101 articles were reviewed in detail. Cognitive functions affected include memory, attention/concentration, problem solving, learning, executive function, processing speed, and social cognition. Cognitive impairment impacts the ability of individuals to carry out activities of daily living, work productively, function socially, and adhere to treatment. These effects have economic ramifications through increased direct and indirect costs associated with the treatment of schizophrenia. The literature revealed 39 PRO instruments that have been used to assess functioning. However, no single instrument captures all key concepts of importance to patients with schizophrenia.
CONCLUSION: The significant burden from CIAS for patients and society has implications for designing future treatments and health strategies to improve functional outcomes.

Entities:  

Mesh:

Year:  2012        PMID: 22351433     DOI: 10.1007/s12325-012-0001-4

Source DB:  PubMed          Journal:  Adv Ther        ISSN: 0741-238X            Impact factor:   3.845


  21 in total

1.  Reduced Short-Latency Afferent Inhibition in Prefrontal but not Motor Cortex and Its Association With Executive Function in Schizophrenia: A Combined TMS-EEG Study.

Authors:  Yoshihiro Noda; Mera S Barr; Reza Zomorrodi; Robin F H Cash; Tarek K Rajji; Faranak Farzan; Robert Chen; Tony P George; Zafiris J Daskalakis; Daniel M Blumberger
Journal:  Schizophr Bull       Date:  2018-01-13       Impact factor: 9.306

2.  Habituation during encoding: A new approach to the evaluation of memory deficits in schizophrenia.

Authors:  Suzanne N Avery; Maureen McHugo; Kristan Armstrong; Jennifer U Blackford; Simon Vandekar; Neil D Woodward; Stephan Heckers
Journal:  Schizophr Res       Date:  2020-07-28       Impact factor: 4.939

3.  Harnessing cognitive neuroscience to develop new treatments for improving cognition in schizophrenia: CNTRICS selected cognitive paradigms for animal models.

Authors:  Holly Moore; Mark A Geyer; Cameron S Carter; Deanna M Barch
Journal:  Neurosci Biobehav Rev       Date:  2013-09-30       Impact factor: 8.989

4.  Protocol to evaluate the impact of yoga supplementation on cognitive function in schizophrenia: a randomised controlled trial.

Authors:  Triptish Bhatia; Sati Mazumdar; Nagendra Narayan Mishra; Raquel E Gur; Ruben C Gur; Vishwajit Laxmikant Nimgaonkar; Smita Neelkanth Deshpande
Journal:  Acta Neuropsychiatr       Date:  2014-10       Impact factor: 3.403

5.  Divergence of subjective and performance-based cognitive gains following cognitive training in schizophrenia.

Authors:  Emily B H Treichler; Michael L Thomas; Andrew W Bismark; William C Hochberger; Melissa Tarasenko; John Nungaray; Lauren Cardoso; Yash B Joshi; Wen Zhang; Joyce Sprock; Neal Swerdlow; Amy N Cohen; Gregory A Light
Journal:  Schizophr Res       Date:  2019-01-16       Impact factor: 4.939

6.  Effect of needs-assessment-based psychoeducation for families of patients with schizophrenia on quality of life of patients and their families: A controlled study.

Authors:  Viktoria Omranifard; Azam Yari; Gholam Reza Kheirabadi; Mahnaz Rafizadeh; Mohammad Reza Maracy; Sima Sadri
Journal:  J Educ Health Promot       Date:  2014-11-29

7.  Effects of needs-assessment-based psycho-education of schizophrenic patients' families on the severity of symptoms and relapse rate of patients.

Authors:  Gholam Reza Kheirabadi; Mahnaz Rafizadeh; Victoria Omranifard; Azam Yari; Mohammad Reza Maracy; Tayebe Mehrabi; Sima Sadri
Journal:  Iran J Nurs Midwifery Res       Date:  2014-11

8.  Treatment outcomes in schizophrenia: qualitative study of the views of family carers.

Authors:  Joanne Lloyd; Helen Lloyd; Ray Fitzpatrick; Michele Peters
Journal:  BMC Psychiatry       Date:  2017-07-21       Impact factor: 3.630

9.  Assessing the synergy between cholinomimetics and memantine as augmentation therapy in cognitive impairment in schizophrenia. A virtual human patient trial using quantitative systems pharmacology.

Authors:  Hugo Geerts; Patrick Roberts; Athan Spiros
Journal:  Front Pharmacol       Date:  2015-09-22       Impact factor: 5.810

10.  Validation of the Chinese version of Brief Assessment of Cognition in Schizophrenia.

Authors:  Liang-Jen Wang; Pao-Yen Lin; Yu Lee; Yu-Chi Huang; Su-Ting Hsu; Chi-Fa Hung; Chih-Ken Chen; Yi-Chih Chen; Ya-Ling Wang; Ming-Che Tsai
Journal:  Neuropsychiatr Dis Treat       Date:  2016-10-31       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.